A Houston-based compounding pharmacy that was recently roped into Eli Lilly’s fight against knockoff GLP-1s has landed in the FDA’s crosshairs for the second time in less than a year. | The FDA has ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Eli Lilly (Symbol: LLY) entered into oversold territory, hitting an RSI reading of 29.5 ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Shares of AstraZeneca (AZN), Pfizer (PFE), Eli Lilly (LLY), Novo Nordisk (NVO), Johnson & Johnson (JNJ), GSK (GSK), and Sanofi (SNY) all declined. Gold futures climbed and the yield on the 10-year ...

The results could be harmful to them in more ways than one. Despite this issue, Eli Lilly remains a top stock to buy. As everyone who follows equity markets knows, stocks are feeling the heat from ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly ... of select Lilly medicines, including Zepbound, through third-party pharmacy ...